GET DAILY SIGNALSCellectar Biosciences (CLRB) Reports Q3 2026 Loss in Line With Estimates, Shifts Focus to Phase 3 Milestones
Key Takeaways
- Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, matching the consensus estimate of a $0.46 loss.
- The net loss widened from $4.4 million, or $1.41 per share, in the same quarter a year earlier, largely on higher clinical-trial spending.
- Research and development (R&D) expense rose to $5.4 million from $2.5 million a year ago, driven by the Phase 3 confirmatory trial and the CLR 125 breast-cancer study.
- Cash and cash equivalents stood at $24.6 million as of September 30, 2026, which management says funds operations into the second quarter of 2027.
- The company reaffirmed plans to dose the first patient in its Phase 3 trial in the first quarter of 2027 and to file for U.S. accelerated approval in the first half of 2027.
Why These Quarterly Results Matter
Cellectar Biosciences is a late-stage clinical biopharmaceutical company without product revenue, so its quarterly updates are evaluated primarily on cash burn, trial advancement, and regulatory progress rather than top-line growth. The firm is developing its lead candidate, iopofosine I 131, for Waldenström macroglobulinemia (WM), a rare blood cancer. Each earnings release draws attention because the share price hinges on clinical milestones and the route to a New Drug Application. With R&D outlays climbing ahead of a confirmatory Phase 3 study and a cash runway that stretches only into mid-2027, this report serves as a checkpoint on whether the company can hit key catalysts before seeking additional capital.
The Quarter in Detail
For the three months ended September 30, 2026, CLRB posted a net loss attributable to common stockholders of $8.0 million, or $0.46 per basic and diluted share, versus a loss of $4.4 million, or $1.41 per share, in the year-ago period. The figure aligned with the analyst consensus of a $0.46 loss per share, and the company recorded no revenue.
R&D expenses climbed to $5.4 million from $2.5 million a year earlier, reflecting startup costs for the Phase 3 confirmatory trial of iopofosine I 131 plus increased activity in the Phase 1b CLR 125 study in triple-negative breast cancer. General and administrative expenses edged higher to $2.7 million from $2.3 million, driven mainly by professional fees and personnel costs.
Cash and cash equivalents totaled $24.6 million at quarter-end, up from $13.2 million at the close of 2025 after a May 2026 financing. Management stated that this balance supports budgeted operations into the second quarter of 2027.
Investor Focus and Market Sentiment
An in-line loss shifts attention squarely to execution and timeline risks. CLRB shares have faced pressure in recent months amid concerns over the cash runway and milestone-linked warrant conditions. Phase 2b data for iopofosine I 131 remain supportive, yet the market remains sensitive to any delays in clinical or regulatory timelines. Primary risks include the need for further financing, share-price hurdles tied to warrant proceeds, and the path to accelerated approval. Sentiment is likely to stay measured until the company shows concrete progress on first-patient dosing in the Phase 3 trial. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What to Watch Going Forward
The key near-term catalyst remains the planned first-patient dosing in the confirmatory Phase 3 trial of iopofosine I 131, targeted for the first quarter of 2027. That study will enroll 100 patients per arm and use progression-free survival as the primary endpoint.
Management intends to submit an NDA in the first half of 2027 for accelerated approval in the post-second-line, post-BTK-inhibitor Waldenström macroglobulinemia setting. The company has reported an 87.5% overall response rate and a 16.0-month median duration of response in patients evaluated right after BTK-inhibitor therapy.
Investors will track R&D spending as costs rise with Phase 3 startup and the CLR 125 program. Given the cash runway extending only into the second quarter of 2027, additional financing may be required before major regulatory milestones. Any slippage in enrollment or filing timelines, along with updates on the CLR 125 study, could influence the stock’s trajectory.
How I Incorporate Tickeron Tools
When evaluating clinical-stage names like CLRB, I often run quick scans with Tickeron’s AI Screener to compare fundamentals, volatility, and sector peers. It helps surface relevant data points without replacing my own fundamental review, and I find the customizable filters useful for narrowing focus ahead of catalyst-heavy quarters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CLRB's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for CLRB moved out of oversold territory on October 23, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 31 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 63 cases where CLRB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CLRB as a result. In 72 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for CLRB just turned positive on October 23, 2026. Looking at past instances where CLRB's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +11.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in 183 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
CLRB broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CLRB entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.396) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. CLRB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer
Industry Biotechnology
Advertisement